AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Panel discussion
Date
22 Sep 2020Session
AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancerPresenters
Ignace VergoteAuthors
A. Oaknin1, I.L. Ray-Coquard2, T. Herzog3, I.B. Vergote4Author affiliations
- 1 Medical Oncology Dept., Vall d`Hebron University Hospital Institut d'Oncologia, 8035 - Barcelona/ES
- 2 Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR
- 3 Gynecologic Oncology, University of Cincinnati Cancer Institute, University of Cincinnati Medical Center, 45219 - Cincinnati/US
- 4 Department Of Gynecology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
Resources
Resources from the same session
Chair’s welcome and introductions
Presenter: Ana Oaknin
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Pioneering with PARP inhibition: rationale for maintenance therapy in newly diagnosed ovarian cancer
Presenter: Thomas Herzog
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Optimising clinical outcomes: the case for personalised medicine in ovarian cancer
Presenter: Ignace Vergote
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Summary and meeting close
Presenter: Ana Oaknin
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Broadening horizons: new data and combinations with PARP inhibitors
Presenter: Isabelle Ray-Coquard
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.